IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Adaptimmune Therapeutics (ADAPY)

CUSIP: 00653A107 | US | Healthcare · Biotechnology | Micro Cap | 382 institutional holders

Quarters

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q1 2026

Rhumbline Advisers3,661
0.0% of portfolio›$72
StyleTurnoverLocationFiled
Rhumbline Advisers
3,661$720.0%IndexVery LowBoston, MA2026-05-12